Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Prognostic, Predictive, and POC: Biomarkers from Research to Clinic

Scott Lippman's Biography

Scott Lippman, Associate Vice Chancellor, University of California-San Diego

Dr. Lippman is the director of the UC San Diego Moores Cancer Center (MCC), the only NCI-designated comprehensive cancer center in the region. He is Senior Associate Dean and Associate Vice Chancellor for Cancer Research and Care, Professor of Medicine, and Chugai Pharmaceutical Chair at UC San Diego, and adjunct professor at the Salk Institute for Biological Studies, Sanford-Burnham Medical Research Institute, and MD Anderson Cancer Center (MDACC). Prior to arriving at MCC in 2012, Dr. Lippman was chair of the Department of Thoracic/Head and Neck Medical Oncology at MDACC. Dr. Lippman brings more than 25 years of experience as principal investigator of translational research involving investigator-initiated clinical trials and maintains an active clinical practice. His research interests include clinical and translational research focused on head and neck and lung cancer; genetic drivers of cancer and premalignancy; predictive molecular signatures and biomarkers for clinical response in solid tumors; and design of trials using molecular targets and markers for cancer prevention and therapy. Since 1990, he has had continuous funding from the NCI, including as principal investigator of major programmatic grants to develop personalized or precision medicine. He has participated in the national leadership of clinical/translational research planning and development within the NCI Cooperative Group setting and currently sits on the NIH Clinical Trials/Translational Research Advisory Committee and chairs an NIH Study Section. He serves on several NCI advisory boards, NCI cancer center external advisory boards and journal editorial boards. Dr. Lippman has served on the United States Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee and was elected to the board of directors for the American Association for Cancer Research (AACR), Association of American Cancer Institutes and National Comprehensive Cancer Network. He received his medical degree from the Johns Hopkins University School of Medicine and is triple-board certified in internal medicine, hematology and medical oncology. Author of more than 350 publications in high-impact journals, including The New England Journal of Medicine, JAMA, PNAS, and The Lancet, J Clin Oncol and chapters in major medical textbooks, Dr. Lippman has received many awards, among them the ASCO-American Cancer Society Award, AACR Cancer Research and Prevention Foundation Award, ASCO Statesman Award and was elected to the prestigious Association of American Physicians.”

Scott Lippman Image

Targeting Genetic Drivers in Pre-malignancy and Cancer

Friday, 16 January 2015 at 14:00

Add to Calendar ▼2015-01-16 14:00:002015-01-16 15:00:00Europe/LondonTargeting Genetic Drivers in Pre-malignancy and CancerPrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California,

The identification of genetic drivers in certain advanced cancers has led to major clinical advances in personalized therapy by targeting these drivers with selective inhibitors (e.g., EGFR and ALK in lung adenocarcinoma). Genetic drivers of cancer progression and metastasis can occur in premalignancy. Cyclin D1 amplification was among the first genetic drivers in head and neck (HN) premalignant lesions and drug targeting of Cyclin D1 produced early promising prevention results. Several retrospective studies suggested that loss of heterozygosity (LOH) at certain loci were genetic drivers in oral premalignant lesions (OPLs). LOH profiles were recently shown to prospectively stratify patients with low-grade oral dysplasia at low risk for progression to oral cancer from those with greater risk. Our recently completed EPOC (Erlotinib Prevention of Oral Cancer) phase III multicenter trial validated specific LOH profiles as genetic drivers. EPOC randomized 150 OPL patients to erlotinib or placebo. While primary endpoint analysis was negative, provocative secondary analyses showed a trend of erlotinib activity during the 12-month therapy (lost after stopping the drug) and that erlotinib-induced grade 2+ skin rash was associated with a highly significant reduction in oral cancer-free survival (vs. patients without rash). EPOC has also provided specimens for targeted genomic studies identifying potential genetic drivers in high-risk OPLs (e.g., PIK3CA). Very recent studies of a) lung carcinogenesis have identified early genetic drivers of squamous cell carcinoma (e.g., 3q26 amplification) and b) HN premalignancy in China have identified oncogenic NOTCH1 driver mutations in OPLs. This presentation will focus on genetic drivers in the context of HN and lung cancer.

Add to Calendar ▼2015-01-15 00:00:002015-01-16 00:00:00Europe/LondonPrognostic, Predictive, and POC: Biomarkers from Research to ClinicPrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California,